Mostrando 10 resultados de: 18
Filtros aplicados
Publisher
Clinical Pharmacology and Therapeutics(2)
Drug Metabolism and Drug Interactions(2)
Pharmacogenomics Journal(2)
Acta Psychiatrica Scandinavica(1)
Clinical Chemistry and Laboratory Medicine(1)
Área temáticas
Farmacología y terapéutica(13)
Enfermedades(11)
Bioquímica(7)
Fisiología humana(3)
Medicina y salud(3)
Área de conocimiento
Farmacología(12)
Genética(9)
Migración humana(1)
Psicopatología(1)
Trastorno depresivo mayor(1)
Clinical implementation of pharmacogenetics and personalized drug prescription based on e-health: The MedeA initiative
ArticleAbstract:Palabras claves:Autores:Adrián LLerena, Cobaleda J., de Andrés F., Mata-Martín C., Penãs-Lledó E.M., Pijierro A., Sánchez C.L.Fuentes:scopusAssessment of the debrisoquin and dextromethorphan phenotyping tests by gaussian mixture distributions analysis
ArticleAbstract: From a sample of 149 unrelated Spaniards, individuals were phenotyped for their ability to hydroxylaPalabras claves:Autores:Adrián LLerena, Avram M., Benitez Rodriguez J., Cobaleda J., Gibbons R., Henthorn T., Krejcie T., Martinez C.Fuentes:scopusAcetylator polymorphism in Parkinson's disease
ArticleAbstract: Acetylator phenotype has been determined using sulphamethazine in 100 patients with Parkinson's disePalabras claves:acetylator phenotype, debrisoquine oxidation, drug polymorphism, Parkinsonism, sulphamethazineAutores:Adrián LLerena, Benitez Rodriguez J., Cobaleda J., Fernandez-Gundin M.J., Jimenez F.J., Ladero J.M., Martinez C., Muñoz J.J.Fuentes:scopusDetermination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: Application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship
ArticleAbstract: The drug-metabolizing cytochrome P450 (CYP) enzyme CYP2D6 is involved in the metabolism of several cPalabras claves:CYP2D6, debrisoquine, HPLC, Metabolic ratioAutores:Adrián LLerena, Berecz R., Cáceres M.C., Cobaleda J., Dorado P., González I.Fuentes:scopusGenomic Ancestry, CYP2D6, CYP2C9, and CYP2C19 Among Latin Americans
ArticleAbstract: We present the distribution of CYP2D6, CYP2C9, and CYP2C19 variants and predicted phenotypes in 33 nPalabras claves:Autores:Adrián LLerena, Alvárez M., Barrantes R., Borbón-Orejuela A., Calzadilla L.R., Céspedes-Garro C., Cobaleda J., de Andrés F., Delgado R., Dorado P., Enrique Terán, Estévez-Carrizo F.E., Ferreiro V., Francisco J.López Hernández, Fricke-Galindo I., Galaviz-Hernandez C., Garza-Ocañas L., Gilman R.H., Grazina M., Humberto Fariñas, Jiménez-Arce G., Jung-Cook H., Lares-Aseff I., Lazalde-Ramos B.P., López-López M., Michelin L.A., Monroy-Jaramillo N., Moya G.E., Naranjo M.E.G., Ortega-Vázquez A., Ortiz-López R., Penãs-Lledó E.M., Pérez B., Pérez-Páramo Y.X., Ramírez-Roa R., Remírez D., Rodeiro I., Rodrigues-Soares F., Rojas-Martinez A., Santiago Terán, Sarmiento A.P., Scliar M.O., Sosa-Macías M.G., Tarazona-Santos E.M., Tinoco C.A., Zamudio R.Fuentes:googlescopusHigh frequency of CYP2D6 ultrarapid metabolizers in Spain: Controversy about their misclassification in worldwide population studies
ArticleAbstract: A high frequency (7-10%) of CYP2D6 ultrarapid metabolizers estimated from the genotype (gUMs) has bePalabras claves:Autores:Adrián LLerena, Cobaleda J., de Andrés F., Delgado A., Naranjo M.E.G., Penãs-Lledó E.M.Fuentes:scopusIncreased risk for major depression associated with the short allele of the serotonin transporter promoter region (5-HTTLPR-S) and the CYP2C9*3 allele
Conference ObjectAbstract: In the present study, we aimed to analyze the potential relevance of the polymorphism in the promotePalabras claves:5-HTTLPR, CYP2C9, genetic polymorphism, major depression, SerotoninAutores:Adrián LLerena, Cáceres M.C., Cobaleda J., Dorado P., González A.P., Penãs-Lledó E.M.Fuentes:scopusEvaluation of drug-metabolizing enzyme hydroxylation phenotypes in Hispanic populations: The CEIBA cocktail
ReviewAbstract: Interindividual differences in response to drug treatments are mainly caused by differences in drugPalabras claves:Cocktail, Cytochrome P450 (CYP), Genotype, Hispanics, PhenotypeAutores:Adrián LLerena, Alonso-Vilatela E., Alvárez M., Barrantes R., Borbón-Orejuela A., Calzadilla L.R., Céspedes-Garro C., Cobaleda J., de Andrés F., Delgado R., Dorado P., Enrique Terán, Estévez-Carrizo F.E., Ferreiro V., Fiedler J., Francisco J.López Hernández, Galaviz-Hernandez C., Garza-Ocañas L., González-Vacarezza N., Grazina M., Herrera L., Jiménez-Arce G., LARES, Lazalde-Ramos B.P., Leonardo J. Beltrán, López-López M., Monroy-Jaramillo N., Moya G.E., Naranjo M.E.G., Natalia Heras, Ochoa-Morales A., Ortega-Vázquez A., Ortiz-López R., Penãs-Lledó E.M., Pérez B., Pérez-Páramo Y.X., Ramírez-Roa R., Remírez D., Rodeiro I., Rojas-Martinez A., Rojas-Ponce R., Sarmiento A.P., Sosa-Macías M.G., Tarazona-Santos E.M., Vázquez T.C., Yescas-Gómez P.Fuentes:scopusInterethnic differences in UGT1A4 genetic polymorphisms between Mexican Mestizo and Spanish populations
ArticleAbstract: UDP-glucuronosyltransferase 1A4 (UGT1A4) is a phase II drug-metabolizing enzyme that catalyzes the gPalabras claves:Glucuronidation, Interethnic differences, Mexican-Mestizo, Spaniards, UGT1A4Autores:Adrián LLerena, Alonso M.E., Cobaleda J., Dorado P., Gallego-Aguilera A., López M.L., MELANIE BRIGETTE ARROYO LOPEZ, Monroy-Jaramillo N., Ortega A., Penãs-Lledó E.M., Silva-Zolezzi I.Fuentes:googlescopusInterethnic differences in drug metabolism: Influence of genetic and environmental factors on debrisoquine hydroxylation phenotype
Conference ObjectAbstract: Genetic and environmental factors are determinants of the interindividual and interethnic variabilitPalabras claves:CYP2D6, debrisoquine, gender, pharmacogenetics, smokingAutores:Adrián LLerena, Benitez Rodriguez J., Cobaleda J., Martínez C.Fuentes:scopus